Combination therapies for lysosomal storage disease: Is the whole greater than the sum of its parts?

Human Molecular Genetics

Volumn 20, Issue , 2011, Pages

  Hawkins Salsbury, Jacqueline A ^a   Reddy, Adarsh S ^a   Sands, Mark S ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME;

ARTICLE; CHILD; ENZYME DEFICIENCY; ENZYME REPLACEMENT; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYSOSOME; LYSOSOME STORAGE DISEASE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; VIRAL GENE THERAPY;

ANIMALS; COMBINED MODALITY THERAPY; GENE THERAPY; GENETIC VECTORS; HUMANS; LYSOSOMAL STORAGE DISEASES; PHENOTYPE;

EID: 79956023383     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr112     Document Type: Article

References (85)

1. Scriver, C.R. (2001) The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, New York.
2. Meikle, P.J., Hopwood, J.J., Clague, A.E. and Carey, W.F. (1999) Prevalence of lysosomal storage disorders. JAMA, 281, 249-254.
3. Dionisi-Vici, C., Rizzo, C., Burlina, A.B., Caruso, U., Sabetta, G., Uziel, G. and Abeni, D. (2002) Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey. J. Pediatr., 140, 321-327.
4. Applegarth, D.A., Toone, J.R. and Lowry, R.B. (2000) Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics, 105, e10.
5. Villani, G.R., Gargiulo, N., Faraonio, R., Castaldo, S., Gonzalez, Y.R.E. and Di Natale, P. (2007) Cytokines, neurotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB. J. Neurosci. Res., 85, 612-622.
6. Roversi, F.M., Galdieri, L.C., Grego, B.H., Souza, F.G., Micheletti, C., Martins, A.M. and D'Almeida, V. (2006) Blood oxidative stress markers in Gaucher disease patients. Clin. Chim. Acta., 364, 316-320.
7. Fu, R., Yanjanin, N.M., Bianconi, S., Pavan, W.J. and Porter, F.D. (2010) Oxidative stress in Niemann-Pick disease, type C. Mol. Genet. Metab., 101, 214-218.
8. Wei, H., Kim, S.J., Zhang, Z., Tsai, P.C., Wisniewski, K.E. and Mukherjee, A.B. (2008) ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum. Mol. Genet., 17, 469-477.
9. Fukuda, T., Ewan, L., Bauer, M., Mattaliano, R.J., Zaal, K., Ralston, E., Plotz, P.H. and Raben, N. (2006) Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann. Neurol., 59, 700-708.
10. Koenig, M.L., Jope, R.S., Baker, H.J. and Lally, K.M. (1987) Reduced Ca2+ flux in synaptosomes from cats with GM1 gangliosidosis. Brain Res., 424, 169-176.
11. Kiselyov, K. and Muallem, S. (2008) Mitochondrial Ca2+ homeostasis in lysosomal storage diseases. Cell Calcium, 44, 103-111.
12. Ginzburg, L. and Futerman, A.H. (2005) Defective calcium homeostasis in the cerebellum in a mouse model of Niemann-Pick A disease. J. Neurochem., 95, 1619-1628.
13. Woloszynek, J.C., Coleman, T., Semenkovich, C.F. and Sands, M.S. (2007) Lysosomal dysfunction results in altered energy balance. J. Biol. Chem., 282, 35765-35771.
14. Woloszynek, J.C., Kovacs, A., Ohlemiller, K.K., Roberts, M. and Sands, M.S. (2009) Metabolic adaptations to interrupted glycosaminoglycan recycling. J. Biol. Chem., 284, 29684-29691.
15. Burstein, Y., Zakuth, V., Rechavi, G. and Spirer, Z. (1987) Abnormalities of cellular immunity and natural killer cells in Gaucher's disease. J. Clin. Lab. Immunol., 23, 149-151.
16. Daly, T.M., Lorenz, R.G. and Sands, M.S. (2000) Abnormal immune function in vivo in a murine model of lysosomal storage disease. Pediatr. Res., 47, 757-762.
17. Shapiro, E.G., Lockman, L.A., Balthazor, M. and Krivit, W. (1995) Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J. Inherit. Metab. Dis., 18, 413-429.
18. Krivit, W., Aubourg, P., Shapiro, E. and Peters, C. (1999) Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Curr. Opin. Hematol., 6, 377-382.
19. Krivit, W., Peters, C. and Shapiro, E.G. (1999) Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr. Opin. Neurol., 12, 167-176.
20. Krivit, W. (2002) Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv. Pediatr., 49, 359-378.
21. Fratantoni, J.C., Hall, C.W. and Neufeld, E.F. (1968) Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science, 162, 570-572.
22. Neufeld, E.F. and Fratantoni, J.C. (1970) Inborn errors of mucopolysaccharide metabolism. Science, 169, 141-146.
23. Rosenfeld, M.A., Yoshimura, K., Trapnell, B.C., Yoneyama, K., Rosenthal, E.R., Dalemans, W., Fukayama, M., Bargon, J., Stier, L.E., Stratford-Perricaudet, L. et al. (1992) In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell, 68, 143-155.
24. Smith, T.A., Mehaffey, M.G., Kayda, D.B., Saunders, J.M., Yei, S., Trapnell, B.C., McClelland, A. and Kaleko, M. (1993) Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat. Genet., 5, 397-402.
25. Yang, Y., Nunes, F.A., Berencsi, K., Furth, E.E., Gonczol, E. and Wilson, J.M. (1994) Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl Acad. Sci. USA, 91, 4407-4411.
26. Jin, H.K. and Schuchman, E.H. (2003) Ex vivo gene therapy using bone marrow-derived cells: combined effects of intracerebral and intravenous transplantation in a mouse model of Niemann-Pick disease. Mol. Ther., 8, 876-885.
27. Miranda, S.R., Erlich, S., Friedrich, V.L. Jr., Gatt, S. and Schuchman, E.H. (2000) Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann-Pick disease. Gene Ther., 7, 1768-1776.
28. Wolfe, J.H., Sands, M.S., Barker, J.E., Gwynn, B., Rowe, L.B., Vogler, C.A. and Birkenmeier, E.H. (1992) Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature, 360, 749-753.
29. Watson, D.J., Longhi, L., Lee, E.B., Fulp, C.T., Fujimoto, S., Royo, N.C., Passini, M.A., Trojanowski, J.Q., Lee, V.M., McIntosh, T.K. et al. (2003) Genetically modified NT2N human neuronal cells mediate long-term gene expression as CNS grafts in vivo and improve functional cognitive outcome following experimental traumatic brain injury. J. Neuropathol. Exp. Neurol., 62, 368-380.
30. Hofling, A.A., Devine, S., Vogler, C. and Sands, M.S. (2004) Human CD34+ hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage disease. Mol. Ther., 9, 856-865.
31. Stein, C.S., Kang, Y., Sauter, S.L., Townsend, K., Staber, P., Derksen, T.A., Martins, I., Qian, J., Davidson, B.L. and McCray, P.B. Jr. (2001) In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. Mol. Ther., 3, 850-856.
32. Kobayashi, H., Carbonaro, D., Pepper, K., Petersen, D., Ge, S., Jackson, H., Shimada, H., Moats, R. and Kohn, D.B. (2005) Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol. Ther., 11, 776-789.
33. Bosch, A., Perret, E., Desmaris, N., Trono, D. and Heard, J.M. (2000) Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum Gene Ther., 11, 1139-1150.
34. Wu, Z., Asokan, A. and Samulski, R.J. (2006) Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther., 14, 316-327.
35. Watson, D.J., Kobinger, G.P., Passini, M.A., Wilson, J.M. and Wolfe, J.H. (2002) Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol. Ther., 5, 528-537.
36. Sands, M.S. and Davidson, B.L. (2006) Gene therapy for lysosomal storage diseases. Mol. Ther., 13, 839-849.
37. Medin, J.A., Tudor, M., Simovitch, R., Quirk, J.M., Jacobson, S., Murray, G.J. and Brady, R.O. (1996) Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc. Natl Acad. Sci. USA, 93, 7917-7922.
38. Sano, R., Tessitore, A., Ingrassia, A. and d'Azzo, A. (2005) Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice corrects neuronal pathology. Blood, 106, 2259-2268.
39. Hofling, A.A., Vogler, C., Creer, M.H. and Sands, M.S. (2003) Engraftment of human CD34+ cells leads to widespread distribution of donor-derived cells and correction of tissue pathology in a novel murine xenotransplantation model of lysosomal storage disease. Blood, 101, 2054-2063.
40. Meyerrose, T.E., Roberts, M., Ohlemiller, K.K., Vogler, C.A., Wirthlin, L., Nolta, J.A. and Sands, M.S. (2008) Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease. Stem Cells, 26, 1713-1722.
41. Liu, C., Dunigan, J.T., Watkins, S.C., Bahnson, A.B. and Barranger, J.A. (1998) Long-term expression, systemic delivery, and macrophage uptake of recombinant human glucocerebrosidase in mice transplanted with genetically modified primary myoblasts. Hum. Gene Ther., 9, 2375-2384.
42. Liu, C., Bahnson, A.B., Dunigan, J.T., Watkins, S.C. and Barranger, J.A. (1998) Long-term expression and secretion of human glucocerebrosidase by primary murine and human myoblasts and differentiated myotubes. J. Mol. Med., 76, 773-781.
43. Smith, B.F., Hoffman, R.K., Giger, U. and Wolfe, J.H. (1990) Genes transferred by retroviral vectors into normal and mutant myoblasts in primary cultures are expressed in myotubes. Mol. Cell. Biol., 10, 3268-3271.
44. Watson, G.L., Sayles, J.N., Chen, C., Elliger, S.S., Elliger, C.A., Raju, N.R., Kurtzman, G.J. and Podsakoff, G.M. (1998) Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. Gene Ther., 5, 1642-1649.
45. Daly, T.M., Okuyama, T., Vogler, C., Haskins, M.E., Muzyczka, N. and Sands, M.S. (1999) Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice. Hum. Gene Ther., 10, 85-94.
46. Tessitore, A., Faella, A., O'Malley, T., Cotugno, G., Doria, M., Kunieda, T., Matarese, G., Haskins, M. and Auricchio, A. (2008) Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle. Mol. Ther., 16, 30-37.
47. Daly, T.M., Vogler, C., Levy, B., Haskins, M.E. and Sands, M.S. (1999) Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc. Natl Acad. Sci. USA, 96, 2296-2300.
48. Cotugno, G., Tessitore, A., Capalbo, A., Annunziata, P., Strisciuglio, C., Faella, A., Aurilio, M., Di Tommaso, M., Russo, F., Mancini, A. et al. (2009) Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses. Hum. Gene Ther., 21, 555-569.
49. Ponder, K.P., Melniczek, J.R., Xu, L., Weil, M.A., O'Malley, T.M., O'Donnell, P.A., Knox, V.W., Aguirre, G.D., Mazrier, H., Ellinwood, N.M. et al. (2002) Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc. Natl Acad. Sci. USA, 99, 13102-13107.
50. Kanaji, A., Kosuga, M., Li, X.K., Fukuhara, Y., Tanabe, A., Kamata, Y., Azuma, N., Yamada, M., Sakamaki, T., Toyama, Y. et al. (2003) Improvement of skeletal lesions in mice with mucopolysaccharidosis type VII by neonatal adenoviral gene transfer. Mol. Ther., 8, 718-725.
51. Daly, T.M., Ohlemiller, K.K., Roberts, M.S., Vogler, C.A. and Sands, M.S. (2001) Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther., 8, 1291-1298.
52. Hartung, S.D., Frandsen, J.L., Pan, D., Koniar, B.L., Graupman, P., Gunther, R., Low, W.C., Whitley, C.B. and McIvor, R.S. (2004) Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol. Ther., 9, 866-875.
53. Jung, S.C., Han, I.P., Limaye, A., Xu, R., Gelderman, M.P., Zerfas, P., Tirumalai, K., Murray, G.J., During, M.J., Brady, R.O. et al. (2001) Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc. Natl Acad. Sci. USA, 98, 2676-2681.
54. Sferra, T.J., Backstrom, K., Wang, C., Rennard, R., Miller, M. and Hu, Y. (2004) Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse. Mol. Ther., 10, 478-491.
55. Rafi, M.A., Zhi Rao, H., Passini, M.A., Curtis, M., Vanier, M.T., Zaka, M., Luzi, P., Wolfe, J.H. and Wenger, D.A. (2005) AAV-mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy. Mol. Ther., 11, 734-744.
56. Lin, D., Donsante, A., Macauley, S., Levy, B., Vogler, C. and Sands, M.S. (2007) Central nervous system-directed AAV2/5-mediated gene therapy synergizes with bone marrow transplantation in the murine model of globoid-cell leukodystrophy. Mol. Ther., 15, 44-52.
57. Ghodsi, A., Stein, C., Derksen, T., Yang, G., Anderson, R.D. and Davidson, B.L. (1998) Extensive beta-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain. Hum. Gene Ther, 9, 2331-2340.
58. Griffey, M., Bible, E., Vogler, C., Levy, B., Gupta, P., Cooper, J. and Sands, M.S. (2004) Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis., 16, 360-369.
59. Lin, D., Fantz, C.R., Levy, B., Rafi, M.A., Vogler, C., Wenger, D.A. and Sands, M.S. (2005) AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2. Mol. Ther., 12, 422-430.
60. Passini, M.A., Macauley, S.L., Huff, M.R., Taksir, T.V., Bu, J., Wu, I.H., Piepenhagen, P.A., Dodge, J.C., Shihabuddin, L.S., O'Riordan, C.R. et al. (2005) AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease. Mol. Ther., 11, 754-762.
61. Frisella, W.A., O'Connor, L.H., Vogler, C.A., Roberts, M., Walkley, S., Levy, B., Daly, T.M. and Sands, M.S. (2001) Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. Mol. Ther., 3, 351-358.
62. Skorupa, A.F., Fisher, K.J., Wilson, J.M., Parente, M.K. and Wolfe, J.H. (1999) Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. Exp. Neurol., 160, 17-27.
63. Chen, Y.H., Chang, M. and Davidson, B.L. (2009) Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat. Med., 15, 1215-1218.
64. Watson, G., Bastacky, J., Belichenko, P., Buddhikot, M., Jungles, S., Vellard, M., Mobley, W.C. and Kakkis, E. (2006) Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. Gene Ther., 13, 917-925.
65. Elliger, S.S., Elliger, C.A., Aguilar, C.P., Raju, N.R. and Watson, G.L. (1999) Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector. Gene Ther., 6, 1175-1178.
66. Griffey, M., Macauley, S.L., Ogilvie, J.M. and Sands, M.S. (2005) AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol. Ther., 12, 413-421.
67. Hennig, A.K., Levy, B., Ogilvie, J.M., Vogler, C.A., Galvin, N., Bassnett, S. and Sands, M.S. (2003) Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. J. Neurosci., 23, 3302-3307.
68. Passini, M.A., Lee, E.B., Heuer, G.G. and Wolfe, J.H. (2002) Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J. Neurosci., 22, 6437-6446.
69. Cearley, C.N. and Wolfe, J.H. (2007) A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J. Neurosci., 27, 9928-9940.
70. Worgall, S., Sondhi, D., Hackett, N.R., Kosofsky, B., Kekatpure, M.V., Neyzi, N., Dyke, J.P., Ballon, D., Heier, L., Greenwald, B.M. et al. (2008) Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther., 19, 463-474.
71. Souweidane, M.M., Fraser, J.F., Arkin, L.M., Sondhi, D., Hackett, N.R., Kaminsky, S.M., Heier, L., Kosofsky, B.E., Worgall, S., Crystal, R.G. et al. (2010) Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations. J. Neurosurg. Pediatr., 6, 115-122.
72. Vitner, E.B., Platt, F.M. and Futerman, A.H. (2010) Common and uncommon pathogenic cascades in lysosomal storage diseases. J. Biol. Chem., 285, 20423-20427.
73. Sands, M.S., Vogler, C., Torrey, A., Levy, B., Gwynn, B., Grubb, J., Sly, W.S. and Birkenmeier, E.H. (1997) Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation. J. Clin. Invest., 99, 1596-1605.
74. Baek, R.C., Kasperzyk, J.L., Platt, F.M. and Seyfried, T.N. (2008) N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. Neurochem. Int., 52, 1125-1133.
75. Pelled, D., Lloyd-Evans, E., Riebeling, C., Jeyakumar, M., Platt, F.M. and Futerman, A.H. (2003) Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin. J. Biol. Chem., 278, 29496-29501.
76. Jeyakumar, M., Norflus, F., Tifft, C.J., Cortina-Borja, M., Butters, T.D., Proia, R.L., Perry, V.H., Dwek, R.A. and Platt, F.M. (2001) Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood, 97, 327-329.
77. Jeyakumar, M., Smith, D.A., Williams, I.M., Borja, M.C., Neville, D.C., Butters, T.D., Dwek, R.A. and Platt, F.M. (2004) NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann. Neurol., 56, 642-649.
78. Lee, J.P., Jeyakumar, M., Gonzalez, R., Takahashi, H., Lee, P.J., Baek, R.C., Clark, D., Rose, H., Fu, G., Clarke, J. et al. (2007) Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat. Med., 13, 439-447.
79. Passini, M.A., Bu, J., Fidler, J.A., Ziegler, R.J., Foley, J.W., Dodge, J.C., Yang, W.W., Clarke, J., Taksir, T.V., Griffiths, D.A. et al. (2007) Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse. Proc. Natl Acad. Sci. USA, 104, 9505-9510.
80. Franco, L.M., Sun, B., Yang, X., Bird, A., Zhang, H., Schneider, A., Brown, T., Young, S.P., Clay, T.M., Amalfitano, A. et al. (2005) Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol. Ther., 12, 876-884.
81. Biswas, S. and LeVine, S.M. (2002) Substrate-reduction therapy enhances the benefits of bone marrow transplantation in young mice with globoid cell leukodystrophy. Pediatr. Res., 51, 40-47.
82. Heldermon, C.D., Ohlemiller, K.K., Herzog, E.D., Vogler, C., Qin, E., Wozniak, D.F., Tan, Y., Orrock, J.L. and Sands, M.S. (2010) Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB. Mol. Ther., 18, 873-880.
83. Khan, M., Haq, E., Giri, S., Singh, I. and Singh, A.K. (2005) Peroxisomal participation in psychosine-mediated toxicity: implications for Krabbe's disease. J. Neurosci. Res., 80, 845-854.
84. Haq, E., Giri, S., Singh, I. and Singh, A.K. (2003) Molecular mechanism of psychosine-induced cell death in human oligodendrocyte cell line. J. Neurochem., 86, 1428-1440.
85. Giri, S., Khan, M., Nath, N., Singh, I. and Singh, A.K. (2008) The role of AMPK in psychosine mediated effects on oligodendrocytes and astrocytes: implication for Krabbe disease. J. Neurochem., 105, 1820-1833.